Patients who develop eruptive keratoacanthomas (KAs) in the setting of PD-1/PD-L1 inhibitor–induced dermatitis are challenging to treat and discontinue immunotherapy at a much higher rate than those without KAs.1-4 We successfully used 3 different nonsurgical anti-inflammatory therapies to treat both immunotherapy-induced dermatitis and concomitant eruptive KAs.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Crow LD, Perkins I, Twigg AR, et al. Treatment of PD-1/PD-L1 Inhibitor–Induced Dermatitis Resolves Concomitant Eruptive Keratoacanthomas. JAMA Dermatol. 2020;156(5):598–600. doi:10.1001/jamadermatol.2020.0176
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.